5Ganz T.Hepcidina regulator of intestinal iron recycling by macrophages,2005(18).
6Kalantar-Zadeh K;Rodriguez RA;Humphreys MH.Association between serum ferritin and measures of inflammation,nutrition and iron in hemodialysis patients,2004(19).
7Ervasti M;Kotisaari S;Romppanen J.In patients who have stainable iron in the bone marrow an elevated plasma transferring receptor value may reflect functional iron deficiency,2004(26).
8Skikne BS;Ahluwalia N;Fergusson B.Effects of erythropoietin therapy on iron absorption in chronic renal failure,2000(135).
9Longnecker RE;Goffinet JA;Hendler ED.Blood loss during maintenance hemodialysis,1974(20).
10Otti T;Khajehdehi P;Fawzy A.Comparison of blood loss with different high-flux and high-efficiency hemodialysis membranes,2001(21).
2Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol,2002, 13:734 -744.
3Agarwal R, Warnock D. Lssues related to iron replacement in chronsic kidney disease. Semin Nephrol,2002,22:479 - 487.
4Bezarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol, 2000 ,( 11 ) :530 -538.
5DeVita MV, Frumkin D, Mittal S, et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol, 2003, ( 60 ) : 335 -340.
6Johnson DW, Herzig KA, Gissane R, et al. Oral versus intravenous iron supplementation in peritoneal dialysis patients. Perit Dial Int, 2001 (Suppl 3) ,(21) :S231 - S235.
7Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron, 1998, (79) :299 -305.
8Aggarwal HK, Nand N, Singh S, et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India, 2003, (51) :170 -174.
9Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis, 1996, (27) :234 -238.
10Van Wyck DB, Roppolo M, Martinez CO, et al. for the United States Iron Sucrose (Vender) Clinical Trials Group. A randomized, controlled trial comparing Ⅳ iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int, 2005, ( 68 ) : 2846 - 2856.
